Out-licensing: Biotechnology/Gene Therapy

Up-to-date access to technology licensing opportunities worldwide.

Out-licensing
Browse

Licensing opportunities

Displaying 11..20 of 72 - per page Previous page Next page
Order by

T-cell Receptor Recognizing Renal Cell Carcinoma

This T-cell receptor recognizes a number of human kidney tumors and is not limited to use in patients with specific MHC types. More

Agonist Epitopes for Renal Cell Carcinoma

Peptides and antigen epitopes specific for RCC for use in the diagnosis, vaccination, or adoptive infusion of antigen specific T cells to treat patients with metastatic RCC More

Patented antigen available to out-license, with applications in ovarian, prostate, breast and lung cancer.

US based researchers are seeking licensing partners for the further development of their antigen which is intended for the treatment of breast cancer but could also have applications in ovarian cancer and other malignancies. More

TMC1, a Deafness-Related Gene

Discovery of dominant and recessive mutations in TMC1 that underlie two forms of hereditary deafness. More

Insect Cell Production of Recombinant Adeno-Associated Virus that Produce Cytotoxic Gene Products and Applications for Solid Tumor Therapy

A new method for targeting solid tumors using gene therapy More

Transfected plasmid construction for the treatment of Parkinson’s disease

Researchers have developed a nucleic acid plasmid construction capable of undergoing transfection into dopaminergic neurons. More

Adoptive Immunotherapy with Autologous Natural Killer Cells

An alternative type of immunotherapy which involves the adoptive transfer of autologous natural killer (NK) cells More

A Gene Expression Signature Identifying Pro-Angiogenic Genes in Ovarian Tumor Endothelial Cell Isolates

Unique proangiogenic biomarkers isolated from ovarian endothelial cells More

Immunogenic Peptides and Methods of Use for Treating Prostrate and Uterine Cancers

Identification and characterization of novel PAGE4 cytotoxic T-cell lymphocyte (CTL) epitopes and enhanced agonist epitopes. More

Efficient Gene Silencing Using tRNA Promoter in a Herpes Virus Vector to Deliver Small Interference RNAs (05-07)

A delivery system for siRNA type therapeutics More

Displaying 11..20 of 72 - per page Previous page Next page
Order by

Your selection

Industry sector: Biotechnology del; Gene therapy del

Browse By

Therapeutic target: Accident and Trauma; Allergy; Blood and forming organs; Cardiovascular; Central Nervous System; Dermatological; Endocrinology; Gastrointestinal; Genetic disorders; Genito-urinary; Hospital and Surgery; Immune related disorders; Infectious diseases; Metabolism; Musculoskeletal; Oncology; Oral Health; Other therapeutic; Respiratory; Sensory organ
Development phase: Early Stage; Preclinical; Phase I; Phase I/II; Phase II; Phase III; Phase III/IV; Preregistration; Registered

Products:	Partnering Search	Company Profiling	Deal Negotiation	PL Intelligence	Reports	Comparision
In-licensing:	Latest records	Industry Sector	Therapeutic Target	Search	Profile your company	Pharma partnering
Out-licensing:	Latest records	Industry Sector	Therapeutic Target	Search	Profile your company	Pharma partnering
Companies:	Profiled companies	Industry Sector	Therapeutic Target	Geographic Location	Search	Add your company
Reports:	Biotechnology	Business Development	Management	Market & Sales	Medical Devices	Pharmaceuticals
Jobs:	Pharmaceutical jobs	Browse jobs	Search for jobs	Create your CV	Employer profiles	Post your jobs
Forums:	Talk to an expert	Industry Gossip	Business Development	What's new	Reports	Services
News:	Deals & Alliances	Development	Financial Results	Financings	Intellectual Property	Regulatory
Events:	Pharma events	Calendar	Organizers	Featured events	Search
Articles:	Business Development	Technologies	Events	Legal and regulatory	Therapeutic
Deals:	Industry Sector	Therapeutic Target	Deals Date	Search	Reports	Press releases
About us:	Our Audience	Case Studies	Newsletter	Careers	FAQ	Contact us